Gregory Tietjen, PhD, is co-founder and Chief Executive Officer of Revalia Bio and an expert in molecular biophysics and biomedical engineering. He earned his PhD from the University of Chicago and completed postdoctoral training at Yale University. As an Assistant Professor at Yale School of Medicine, he focused on leveraging non-transplanted human organs to uncover disease mechanisms and guide the rational design of precision therapies.